Original price was: £89.99.£74.99Current price is: £74.99.
-17%for orders over £200
Semaglutide peptide is a derivative of the naturally occurring GLP-1 used to treat type 2 diabetes. This peptide has been shown to help lose weight. It is known to lower blood sugar levels and enhance insulin secretion. This peptide is also used to lower the risk of heart attack, stroke, or death in people with type 2 diabetes and heart or blood vessel disease.
Semaglutide has been shown to:
Significantly decrease appetite
Lower blood sugar levels
Enhance insulin secretion
Reduced inflammatory marker, C-reactive protein
Improve heart, liver, and lung function
Neuroprotective effects
This product is prepared for RESEARCH USE ONLY and may not be used for other purposes.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the GLP-1 hormone, released in the gut in response to eating. Research shows that Semaglutide may improve heart, liver, and lung function while helping to slow or prevent the effects of Alzheimer’s disease while reducing inflammation. Semaglutide has been shown to significantly decrease appetite by delaying gastric emptying and reducing intestinal motility. Glucagon-Like Peptide-1 (GLP-1) Analog Shown to Stimulate Insulin and Suppress Glucagon Secretion in a Glucose-Dependent Manner.
One role of GLP-1 is to prompt the body to produce more insulin, which reduces blood sugar (glucose). For that reason, semaglutide has been used for more than 15 years to treat Type 2 diabetes.
GLP-1 in higher amounts also interacts with the parts of the brain that suppress your appetite. Because of this, Semaglutide can cause significant weight loss and a reduced risk of diseases associated with being obese or overweight.
Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: Involvement of the PI3K/Akt/GSK-3β pathway
Author links open overlay panelMohamed A Sadek, Esraa A Kandil, Nesrine S El Sayed, Helmy M Sayed, Mostafa A Rabie
The Physiology of Glucagon-like Peptide 1 | Physiological Reviews.” [Online].
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
L Blonde 1, E J Klein, J Han, B Zhang, S M Mac, T H Poon, K L Taylor, M E Trautmann, D D Kim, D M Kendall
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
List of authors.
Mikhail N. Kosiborod, M.D., Steen Z. Abildstrøm, Ph.D., Barry A. Borlaug, M.D., Javed Butler, M.D., Søren Rasmussen, Ph.D., Melanie Davies, M.D., G. Kees Hovingh, M.D., Ph.D., Dalane W. Kitzman, M.D., Marie L. Lindegaard, M.D., D.M.Sc., Daniél V. Møller, M.D., Ph.D., Sanjiv J. Shah, M.D., Marianne B. Treppendahl, M.D., Ph.D., et al., for the STEP-HFpEF Trial Committees and Investigators*
All articles and product information on this website are for educational purposes only. These products are not medicines or drugs and have not been approved to treat or cure any medical condition.
© 2022 All Rights Reserved
Products shown on this website are prepared for RESEARCH USE ONLY and may not be used for other purposes.
